Sector |
|
Compare with Sector peers |
Industry |
|
Compare with Industry peers |
Website | http://www.windlasbiotech.com | |
Market Cap | 471.54 Cr. | |
Enterprise Value(EV) | 371.69 Cr. | 2022-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 21.95 | Trailing Twelve Months Ending 2022-12 |
Price-Earning Ratio (PE) | 10.26 | Trailing Twelve Months Ending 2022-12 |
Industry PE | 32.41 | Trailing Twelve Months Ending 2022-12 |
Book Value / Share | 202.36 | Trailing Twelve Months Ending 2022-12 |
Price to Book Value | 1.11 | Calculated using Price: 225.20 |
Dividend Yield | 1.55 | Period Ending 2022-03 |
No. of Shares Subscribed | 2.09 Cr. | 20,938,941 Shares |
FaceValue | 5 | |
Company Profile | ||
The company provides pharmaceutical development services, large-scale manufacturing services and authentic yet affordable products to its customers and consumers around the world. |
1 Day |
|
+0.38% |
1 Week |
|
-5.62% |
1 Month |
|
-11.65% |
3 Month |
|
-9.87% |
6 Month |
|
-3.68% |
1 Year |
|
+7.19% |
2 Year |
|
|
5 Year |
|
|
10 Year |
|
5 years | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | |
Return on Equity (%) | 9.07 | 40.92 | 11.74 | 7.70 | 12.87 | |
Return on Capital Employed (%) | 14.54 | 40.49 | 15.05 | 9.93 | 14.88 | |
Return on Assets (%) | 3.83 | 22.01 | 7.45 | 4.97 | 9.70 |
Particulars | 6 years | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09* Rs. Cr. |
Shh. Funds | 125 | 194 | 210 | 199 | 395 | 408 | |
Non Curr. Liab. | 21 | 8 | 3 | 4 | 0 | 1 | |
Curr. Liab. | 143 | 96 | 125 | 93 | 94 | 107 | |
Minority Int. | |||||||
Equity & Liab. | 289 | 298 | 338 | 296 | 489 | 516 | |
Non Curr. Assets | 145 | 177 | 170 | 102 | 107 | 112 | |
Curr. Assets | 144 | 120 | 168 | 194 | 382 | 404 | |
Misc. Exp. not W/O | |||||||
Total Assets | 289 | 298 | 338 | 296 | 489 | 516 |
Particulars | 6 years | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-12 Rs. Cr. TTM |
Net Sales | 352 | 307 | 329 | 428 | 466 | 495 | |
Other Income | 4 | 4 | 2 | 3 | 7 | 11 | |
Total Income | 356 | 312 | 331 | 431 | 473 | 505 | |
Total Expenditure | -313 | -269 | -287 | -373 | -414 | -437 | |
PBIDT | 44 | 43 | 44 | 58 | 59 | 68 | |
Interest | -6 | -5 | -3 | -1 | -1 | -1 | |
Depreciation | -17 | -11 | -9 | -13 | -12 | -12 | |
Taxation | -9 | -12 | -8 | -6 | -7 | -10 | |
Exceptional Items | 50 | -22 | |||||
PAT | 11 | 65 | 24 | 16 | 38 | 46 | |
Minority Interest | 0 | ||||||
Share Associate | 0 | -1 | -7 | 0 | |||
Other Related Items | |||||||
Consolidated Net Profit | 11 | 64 | 16 | 16 | 38 | 46 | |
Adjusted EPS | 20 | 35 | 25 | 9 | 17 | 21 |
Particulars | 5 years | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. |
Cash Fr. Operatn. | 35 | 19 | 25 | 11 | 9 | |
Cash Fr. Inv. | -11 | -5 | -14 | -20 | -155 | |
Cash Fr. Finan. | -26 | -6 | -5 | 1 | 130 | |
Net Change | -2 | 7 | 5 | -8 | -15 | |
Cash & Cash Eqvt | 7 | 13 | 18 | 16 | 1 |
Fri, 31 Mar 2023
Closure of Trading Window Intimation of Trading Window Closure |
Fri, 31 Mar 2023
Announcement under Regulation 30 (LODR)-Daily Buy Back of equity shares Submission of daily report in accordance with Regulation 18(i) of the SEBI (Buy-back of Securities) Regulations 2018 |
Thu, 30 Mar 2023
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation Intimation of Schedule of Analyst / Institutional Investor meetings under the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 |
Fri, 31 Mar 2023 |
|
|
|
|
|